Irina Nelepcu

Irina Nelepcu

Auto-generated profile, based on publicly available information

Irina Nelepcu

Vancouver Prostate Centre, Vancouver Coastal Health Research Institutes, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EVElena Ethel Vidal-Calvo
Elena Ethel Vidal-Calvo
AMAnne Martin-Salazar
Anne Martin-Salazar
SCSwati Choudhary
Swati Choudhary
RDRobert Dagil
Robert Dagil
SRSai Sundar Rajan Raghavan
Sai Sundar Rajan Raghavan
ASAli salanti
Ali salanti
Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express is oncofetal chondroitin sulfate (ofCS), which supports disease progression and dissemination in cancer. Here, we report the identification and characterization of phage display-derived antibody fragments recognizing two distinct ofCS epitopes. These antibody fragments show binding affinity to ofCS in the low nanomolar range across a broad selection of solid tumor types in vitro and in vivo with minimal binding to normal, inflamed, or benign tumor tissues. Anti-ofCS antibody drug conjugates and bispecific immune cell engagers based on these targeting moieties disrupt tumor progression in animal models of human and murine cancers. Thus, anti-ofCS antibody fragments hold promise for the development of broadly effective therapeutic and diagnostic applications targeting human malignancies.

13 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NAnader al-nakouzi
nader al-nakouzi
CWChris Kedong Wang
Chris Kedong Wang
HOHtoo Zarni Oo
Htoo Zarni Oo
INIrina Nelepcu
Irina Nelepcu
NLNada Lallous
Nada Lallous
MDMads Daugaard
Mads Daugaard
Lineage plasticity of prostate cancer is associated with resistance to androgen receptor (AR) pathway inhibition (ARPI) and supported by a reactive tumor microenvironment. Here we show that changes in chondroitin sulfate (CS), a major glycosaminoglycan component of the tumor cell glycocalyx and extracellular matrix, is AR-regulated and promotes the adaptive progression of castration-resistant prostate cancer (CRPC) after ARPI. AR directly represses transcription of the 4-O-sulfotransferase gene CHST11 under basal androgen conditions, maintaining steady-state CS in prostate adenocarcinomas. When AR signaling is inhibited by ARPI or lost during progression to non-AR-driven CRPC as a consequence of lineage plasticity, CHST11 expression is unleashed, leading to elevated 4-O-sulfated chondroitin levels. Inhibition of the tumor cell CS glycocalyx delays CRPC progression, and impairs growth and motility of prostate cancer after ARPI. Thus, a reactive CS glycocalyx supports adaptive survival and treatment resistance after ARPI, representing a therapeutic opportunity in patients with advanced prostate cancer.

15 October 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
NKNastaran Khazamipour
Nastaran Khazamipour
HOHtoo Zarni Oo
Htoo Zarni Oo
NANader Al-Nakouzi
Nader Al-Nakouzi
MMMona Marzban
Mona Marzban
NKNasrin Khazamipour
Nasrin Khazamipour
MDMads Daugaard
Mads Daugaard
Glycosaminoglycans are often deprioritized as targets for synthetic immunotherapy due to the complexity of glyco-epitopes and limited options for obtaining specific subtype binding. Solid tumors express proteoglycans that are modified with oncofetal chondroitin sulfate (CS), a modification normally restricted to the placenta. Here, we report the design and functionality of transient chimeric antigen receptor (CAR) T cells with selectivity to oncofetal CS. Following expression in T cells, the CAR could be “armed” with recombinant VAR2CSA lectins (rVAR2) to target tumor cells expressing oncofetal CS. While unarmed CAR T cells remained inactive in the presence of target cells, VAR2-armed CAR T cells displayed robust activation and the ability to eliminate diverse tumor cell types in vitro. Cytotoxicity of the CAR T cells was proportional to the concentration of rVAR2 available to the CAR, offering a potential molecular handle to finetune CAR T cell activity. In vivo, armed CAR T cells rapidly targeted bladder tumors and increased the survival of tumor-bearing mice. Thus, our work indicates that cancer-restricted glycosaminoglycans may be exploited as potential targets for CAR T cell therapy.